Serum and tissue vascular endothelial growth factor predicts prognosis in hepatocellular carcinoma patients after partial liver resection

Hepato-Gastroenterology

Volumn 59, Issue 113, 2012, Pages 93-97

  Zhong, Chong ^a   Wei, Wei ^b   Su, Xiao Kang ^a   Li, Hui Dong ^a   Xu, Fa Bing ^a   Guo, Rong Ping ^b  

^a GUANGZHOU UNIVERSITY OF CHINESE MEDICINE   (China)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

Enzyme linked immunosorbent assay; Hepatocellular carcinoma; Immunohistochemistry; Recurrence; VEGF

Indexed keywords

VASCULOTROPIN;

ARTICLE; BLOOD LEVEL; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOPLASM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PARTIAL HEPATECTOMY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL RATE; TISSUE LEVEL;

CARCINOMA, HEPATOCELLULAR; CHI-SQUARE DISTRIBUTION; CHINA; DISEASE-FREE SURVIVAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATECTOMY; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MULTIVARIATE ANALYSIS; NEOPLASM MICROMETASTASIS; NEOPLASM RECURRENCE, LOCAL; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84863233968     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: 10.5754/hge10638     Document Type: Article

References (36)

1. Parkin DM: Global cancer statistics in the year 2000. Lancet Oncol 2001; 2:533-543.
2. El-Serag HB: Hepatocellular carcinoma: an epidemiologic view. J Clin Gastroenterol 2002; 35: S72-S78.
3. Arii S, Yamaoka Y, Futagawa S, et al.: Results of surgical and non-surgical treatment for small-sized hepatocellular carcinomas: A retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan. Hepatology 2000; 32:1224-1229.
4. Qin LX, Tang ZY: Recent progress in predictive biomarkers for metastatic recurrence of human hepatocellular carcinoma: a review of the literature. J Cancer Res Clin Oncol 2004; 130:497-513.
5. Miura H, Miyazaki T, Kuroda M, et al.: Increased expression of vascular endothelial growth factor in human hepatocellular carcinoma. J Hepatol 1997; 27:854-861. (Pubitemid 27454829)
6. Bergers G, Brekken R, McMahon G, et al.: Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2000; 2:737-744.
7. Guo RP, Zhong C, Shi M, et al.: Clinical value of apoptosis and angiogenesis factors in estimating the prognosis of hepatocellular carcinoma. J Cancer Res Clin Oncol 2006; 132:547-555. (Pubitemid 44078523)
8. Hermanek P, Hutter RV, Sobin LH, et al.: Classification of isolated tumor cells and micrometastasis. Cancer 1999; 86:2668-2673. (Pubitemid 30004671)
9. Edmondson HA, Steiner PE: Primary carcinoma of the liver: a study of 100 cases among 48900 necropsies. Cancer 1954; 7:462-503.
10. Pugh RN, Murray-Lyon IM, Dawson JL, et al.: Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60:646-649.
11. Yamaguchi R, Yano H, Iemura A, et al.: Expression of vascular endothelial growth factor in human hepatocellular carcinoma. Hepatology 1998; 28:68-77. (Pubitemid 28299987)
12. Bruix J, Sherman M, Llovet JM, et al.: Clinical management of hepatocellular carcinoma: conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001; 35:421-430. (Pubitemid 32844200)
13. Nagasue N, Uchida M, Makino Y, et al.: Incidence and factors associated with intrahepatic recurrence following resection of hepatocellular carcinoma. Gastroenterology 1993; 105:488-494. (Pubitemid 23213535)
14. Yamamoto J, Kosuge T, Takayama T, et al.: Recurrence of hepatocellular carcinoma after surgery. Br J Surg 1996; 83:1219-1222. (Pubitemid 26290448)
15. Poon RT, Fan ST, Lo CM, et al.: Intrahepatic recurrence after curative resection of hepatocellular carcinoma. Long-term results of treatment and prognostic factors. Ann Surg 1999; 229:216-222. (Pubitemid 30191795)
16. Folkman J: Endothelial cells and angiogenic growth factors in cancer growth and metastasis. Cancer Metastasis Rev 1990; 9:171-174.
17. Sun HC, Tang Z: Angiogenesis in hepatocellular carcinoma: the retrospectives and perspectives. J Cancer Res Clin Oncol 2004; 130:307-319.
18. Pang R, Poon RT: Angiogenesis and anti-angiogenic therapy in hepatocellular carcinoma. Cancer Lett 2006; 242:151-167. (Pubitemid 44485315)
19. Moon WS, Rhyu KH, Kang MJ, et al.: Over expression of VEGF and angioproietin 2: a key to high vascularity of hepatocellular carcinoma? Mod Pathol 2003; 16:552-557. (Pubitemid 36718436)
20. Unemori EN, Ferrara N, Bauer EA, et al.: Vascular endothelial growth factor induces interstitial collagenase expression in human endothelial cells. J Cell Physiol 1992; 153:557-562.
21. Garzetti GG, Ciavattini A, Lucarini G, et al.: Expression of vascular endothelial growth factor related to 72-kilodalton metalloproteinase immunostaining in patients with serous ovarian tumors. Cancer 1999; 85:2219-2225. (Pubitemid 29215562)
22. Li XM, Tang ZY, Zhou G, et al.: Significance of vascular endothelial growth factor mRNA expression in invasion and metastasis of hepatocellular carcinoma. J Exp Clin Cancer Res 1998; 17:13-17. (Pubitemid 28215959)
23. Kanda M, Nomoto S, Nishikawa Y, et al.: Correlations of the expression of vascular endothelial growth factor B and its isoforms in hepatocellular carcinoma with clinico-pathologicai parameters. J Surg Oncol 2008; 98:190-196.
24. Salgado R, Vermeulen PB, Benoy I, et al.: Platelet number and interleukin-6 correlate with VEGF but not with bFGF serum levels of advanced cancer patients. Br J Cancer 1999; 80:892-897. (Pubitemid 29209856)
25. Schoenleber SJ, Kurtz DM, Talwalkar JA, et al.: Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: systematic review and meta-analysis. Br J Cancer 2009; 100:1385-1392.
26. Chow NH, Hsu PI, Lin XZ, et al.: Expression of vascular endothelial growth factor in normal liver and hepatocellular carcinoma: an immunohistochemical study. Hum Pathol 1997; 28:698-703.
27. Zhang Q, Chen X, Zhou J, et al.: CD147, MMP-2, MMP-9 and MVD-CD34 are significant predictors of recurrence after liver transplantation in hepatocellular carcinoma patients. Cancer Biol Ther 2006; 5:808-814. (Pubitemid 44775139)
28. Kim SJ, Choi IK, Park KH, et al.: Serum vascular endothelial growth factor per platelet count in hepatocellular carcinoma: Correlations with clinical parameters and survival. Jpn J Clin Onco 2004; 34:184-190. (Pubitemid 43102895)
29. Chao Y, Li CP, Chau GY, et al.: Prognostic significance of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin in patients with resectable hepatocellular carcinoma after surgery. Ann Surg Oncol 2003; 10:355-362. (Pubitemid 40486931)
30. Ishii Y, Nakasato Y, Kobayashi S, et al.: A study on angiogenesis-related matrix metalloproteinase networks in primary hepatocellular carcinoma. J Exp Clin Cancer Res 2003; 22:461-470. (Pubitemid 37205405)
31. Poon RT, Ho JW, Tong CS, et al.: Prognostic significance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinoma. Br J Surg 2004; 91:1354-1360. (Pubitemid 39331462)
32. Treiber G, Wex T, Rocken C, et al.: Impact of biomarkers on disease survival and progression in patients treated with octreotide for advanced hepatocellular carcinoma. J Cancer Res Clin Oncol 2006; 132:699-708. (Pubitemid 44337930)
33. Jeng KS, Sheen IS, Wang YC, et al.: Prognostic significance of preoperative circulating vascular endothelial growth factor messenger RNA expression in resectable hepatocellular carcinoma: a prospective study. World J Gastroenterol 2004; 10:643-648.
34. Yamanaka N, Okamoto E, Toyosaka A, et al.: Prognostic factors after hepatectomy for hepatocellular carcinomas. A univariate and multivariate analysis. Cancer 1990; 65:1104-1110. (Pubitemid 20072042)
35. Nakano S, Haratake J, Okamoto K, et al.: Investigation of resected multi-nodular hepatocellular carcinoma: assessment of unicentric or multi-centric genesis from histological and prognosis viewpoint. Am J Gastroenterol 1994; 89:189-193. (Pubitemid 24054177)
36. Llovet JP, Di Bisceglie AM, Bruix J, et al.: Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008; 100:698-711.